PRIMO AUTORE TITOLO RIF. BIBLIOGRAFICO LINK
Derfuss et al Advances in oral immunomodulating therapies in relapsing multiple sclerosis Lancet Neurol 2020; 19: 336–47
Comi et al Evolving concepts in the treatment of relapsing multiple sclerosis Lancet 2017; 389: 1347–56
McGinley et al Diagnosis and Treatment of Multiple Sclerosis A Review JAMA. 2021;325(8):765-779. doi:10.1001/jama.2020.26858
Amato et al Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis BRAIN 2020: 143; 3013–3024
Kalincik et al Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years Neurology 2020
Roy et ACNS Sphingosine 1‑Phosphate Receptor Modulators for Multiple Sclerosis Drugs2021
Chun et al Sphingosine 1‑phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects Drugs (2021) 81:207–231
Comi et al Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial Lancet Neurol 2019; 18: 1009–20
Cohen et al Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial Lancet Neurol 2019; 18: 1021–33
Rocca et al Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis Neurology. 2021 Mar 16;96(11):e1561-e1573
Eijlers et al Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis Neurology. 2019 Oct 1;93(14):e1348-e1359
Manca et al Multiple brain networks support processing speed abilities of patients with multiple sclerosis Postgrad Med. 2019 Sep;131(7):523-532. doi: 10.1080/00325481.2019.1663706. Epub 2019 Sep 16
Meca-Lallana et al Cognitive impairment in multiple sclerosis: diagnosis and monitoring Neurol Sci. 2021 Apr 1. doi: 10.1007/s10072-021-05165-7. Online ahead of print
Lakin et al Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review Neurol Ther. 2021 Apr 20. doi: 10.1007/s40120-021-00239-2. Online ahead of print
Amato et al Treatment of cognitive impairment in multiple sclerosis: position paper J Neurol. 2013 Jun;260(6):1452-68. doi: 10.1007/s00415-012-6678-0. Epub 2012 Nov 23
Vollmer et al Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review Neurol Sci. 2016 Feb;37(2):165-79. doi: 10.1007/s10072-015-2400-1. Epub 2015 Nov 4
DeLuca et al Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS Mult Scler Relat Disord. 2021 Feb;48:102673. doi: 10.1016/j.msard.2020.102673. Epub 2020 Dec 10
Filippi et al MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26
Filippi et al Identifying Progression in Multiple Sclerosis: New Perspectives Ann Neurol. 2020 Sep;88(3):438-452. doi: 10.1002/ana.25808. Epub 2020 Jul 6
Filippi et al Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines Brain. 2019 Jul 1;142(7):1858-1875. doi: 10.1093/brain/awz144
Chard et al Mind the gap: from neurons to networks to outcomes in multiple sclerosis Nat Rev Neurol. 2021 Mar;17(3):173-184. doi: 10.1038/s41582-020-00439-8. Epub 2021 Jan 12
Gasperini et al Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26